Stuart Therapeutics, Inc. Appoints Dave LeCause as Senior Commercial Advisor - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Stuart Therapeutics, Inc. Appoints Dave LeCause as Senior Commercial Advisor

New hire to commercialize a new class of collagen-reparative therapeutics

  • September 18, 2026

  • 2 min

Share

Clinical Scorecard: Stuart Therapeutics, Inc. Appoints Dave LeCause as Senior Commercial Advisor

At a Glance

CategoryDetail
ConditionDry Eye Disease
Key MechanismsCollagen-reparative therapeutics
Target PopulationPatients with dry eye disease
Care SettingBiopharmaceutical development

Key Highlights

  • Stuart Therapeutics develops first-in-class therapeutics for eye diseases.
  • Dave LeCause appointed as senior commercial advisor.
  • ST-100 to begin Phase 3b clinical trials in Q1 2027.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Patients with dry eye disease

          ST-100 is the lead therapeutic candidate.

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Stuart Therapeutics, Inc. Appoints Dave LeCause as Senior Commercial Advisor

            • September 18, 2026

            Related Content

            Reflections on Lumenis Accelerate from Laura Periman, MD

            Optometric Management caught up with Laura Periman, MD, at the Lumenis Accelerate Owner’s Summit in Chicago on August 28 to discuss what attendees could take away from the event, both in clinical pearls and workflows and in practice management lessons.

            • September 1, 2026

            • 4 min
            The Importance of Treating OSD and Lid Margin Disease Preoperatively

            Marjan Farid, MD, discusses her ASCRS Cornea Day presentation on preoperatively treating DED and OSD.

            • April 11, 2026

            • 4 min
            New Immune Target in Dry Eye

            Investigators say rexinoid therapy may represent a new class of dry eye treatment focused on regenerative immune signaling

            • June 30, 2026

            • 3 min